Concepedia

Amy Simon

AS

Statistics

Publications

33

Citations

5.1K

H-Index

23

Active since

1996

Affiliations

Alnylam Pharmaceuticals (United States)(Current)

Tufts Medical Center

Tufts University

Icahn School of Medicine at Mount Sinai

The University of Texas Medical Branch at Galveston

Amy Simon is an author at Alnylam Pharmaceuticals (United States) specializing in life sciences, pharmacology, and medicine.

Publications per year

1996–2024

33

Publications

33

A Highly Durable RNAi Therapeutic Inhibitor of PCSK9

Kevin Fitzgerald, Suellen White, Anna Borodovsky et al. · New England Journal of Medicine · 2016 · 760 citations · Full text

, , +17

Activation of the JAK-STAT pathway by reactive oxygen species

Amy Simon, Usha Rai, Barry L. Fanburg et al. · American Journal of Physiology-Cell Physiology · 1998 · 594 citations

, , +15

Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria

Manisha Balwani, Eliane Sardh, Paolo Ventura et al. · New England Journal of Medicine · 2020 · 592 citations · Full text

, , +14

Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial

Kevin Fitzgerald, Maria Frank-Kamenetsky, Svetlana Shulga‐Morskaya et al. · The Lancet · 2013 · 574 citations

, , +16

An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia

Alfica Sehgal, Scott Barros, Lacramioara Ivanciu et al. · Nature Medicine · 2015 · 297 citations

, , +12

1–5 of 33